Singular Genomics Systems Inc
Singular Genomics Systems, Inc., a life science technology company, develops next generation sequencing and spatial multiomics technology for researchers and clinicians to advance science and medicine. It is involved in the developing of G4, consisting of G4 instrument and associated consumables for various applications, such as max read kits for single cell sequencing, rare variant detection wit… Read more
Singular Genomics Systems Inc (OMIC) - Total Liabilities
Latest total liabilities as of September 2024: $63.30 Million USD
Based on the latest financial reports, Singular Genomics Systems Inc (OMIC) has total liabilities worth $63.30 Million USD as of September 2024.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Singular Genomics Systems Inc - Total Liabilities Trend (2019–2023)
This chart illustrates how Singular Genomics Systems Inc's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
Singular Genomics Systems Inc Competitors by Total Liabilities
The table below lists competitors of Singular Genomics Systems Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Alarko Carrier Sanayi ve Ticaret AS
IS:ALCAR
|
Turkey | TL3.54 Billion |
|
INSTAL KRAKÓW SA
WAR:INK
|
Poland | zł123.34 Million |
|
DLH Holdings Corp
NASDAQ:DLHC
|
USA | $171.32 Million |
|
Fortune Rise Acquisition Corp
NASDAQ:FRLA
|
USA | $11.37 Million |
|
Capital & Regional Plc
PINK:CRPLF
|
USA | $253.90 Million |
|
Mobile Appliance Inc.
KQ:087260
|
Korea | ₩13.56 Billion |
|
Pinago Utama Tbk Pt
JK:PNGO
|
Indonesia | Rp513.71 Billion |
Liability Composition Analysis (2019–2023)
This chart breaks down Singular Genomics Systems Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 7.37 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.51 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.34 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Singular Genomics Systems Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Singular Genomics Systems Inc (2019–2023)
The table below shows the annual total liabilities of Singular Genomics Systems Inc from 2019 to 2023.
| Year | Total Liabilities | Change |
|---|---|---|
| 2023-12-31 | $86.46 Million | +27.80% |
| 2022-12-31 | $67.65 Million | +247.39% |
| 2021-12-31 | $19.48 Million | -76.27% |
| 2020-12-31 | $82.06 Million | +12.56% |
| 2019-12-31 | $72.90 Million | -- |